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Neonate organisms display an intrinsic disability to mount effective immune responses to
infectious agents or conventional vaccines. Whereas low. doses of antigens trigger a suboptimal
response, higher doses are frequently associated with tolerance induction. We investigated the
ability of a plasmid-expressing nucleoprotein of influenza virus to prime a specific cellular
immune response when administered to newborn mice. We found that persistent exposure to
antigen following plasmid inoculation of neonates leads to a vigorous priming of specific CTLs
rather than tolerance induction. The CTLs were cross-reactive against multiple strains of type A
influenza viruses and produced IFNy but no IL-4. The immunity triggered by plasmid
inoculation of neonates was protective in terms of pulmonary virus clearance as well as survival
rate following lethal challenge with influenza virus. Whereas the persistence of the plasmid at the
site of injection was readily demonstrable in adult mice at 3 months after inoculation, mice
immunized as newborns displayed no plasmid at 3 months and very little at month after
injection. Thus, DNA-based immunization of neonates may prove an effective and safe
vaccination strategy for induction of cellular immunity against microbes that cause serious
infectious diseases in the early period of life.
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INTRODUCTION
Various vaccine strategies were shown to induce a
cytotoxic immune response in adult organisms. An
effective induction of CTL immunity depends on the
ability of the vaccine to direct the epitopes to the
MHC-class I pathway of presentation (Townsend et
al., 1985). Live-attenuated recombinant vectors
(Aggarwal et al., 1990; Tartaglia et al., 1992), peptide
or protein formulations in liposomes (Harding et al.,
1991; Nair et al., 1992), lipid-tailed peptides (Allsopp
et al., 1996), or recombinant Ty viruslike particles
(Griffiths et al., 1991) were shown to induce specific
CTL responses. DNA immunization emerged as a
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promising strategy of vaccination tested in numerous
experimental systems and able to trigger in adult
organisms long-term cellular (Ulmer et al., 1993;
Yankauckas et al., 1993) and humoral (Davis et al.,
1993; Robinson et al., 1993) immunity with pro-
tective ability in some cases (Whalen, 1996). DNA-
based vaccination offers some advantages over the
other vaccine strategies: ability to induce a CTL
immune response in absence of vector replication and
strong adjuvants, long duration of memory presum-
ably due to the persistence of the antigen, and a
relatively easy and rapid manufacture procedure that
lowers the fabrication costs (Whalen, 1996).
Compared with adults, young organisms display
particular immune responsiveness to antigens. Early
studies showed that newborns are very susceptible to
tolerance induction for alloantigens (Billingham et al.,
1956) and polysaccharides (Bona et al., 1978) leading
to the paradigm of neonatal tolerance as a mechanism
for self-/nonself-discrimination. More recent studies
however, showed that newborns are able to mount
immune responses, although qualitatively different as
compared with adult organisms. Thus, both in vitro
and in vivo experiments demonstrated that newborn
lymphocytes have an intrinsic tendency to respond via
a Th2 pattern to polyclonal stimulators (Adkins et al.,
1993) or antigens (Barrios et al., 1996), respectively.
Further, high-zone tolerance in neonates was asso-
ciated with a strong Th2 type of immune response
(Forsthuber et al., 1996; Sarzotti et al., 1996),
suggesting that active suppressive mechanisms rather
than precursor deletion may be responsible for
neonatal low responsiveness to foreign antigens.
Recent studies showed that targeting the antigen to
professional antigen-presenting cells (APCs) (Ridge
et al., 1996), use of certain adjuvants (Forsthuber et
al., 1996), and decreasing the dose of immunogen
(Sarzotti et al., 1996) were followed by induction of
significant cellular immune responses in neonates.
Thus, at least in some circumstances, immunization of
newborns triggers Thl and CTL immune responses.
In light of these recent studies, the particular immune
responsiveness of newborns consisting in tolerance
susceptibility and Th2-biased immune responses
seems to be due to predominant presentation of
antigen by nonprofessional APC rather than to
intrinsic characteristics of neonatal T lymphocytes.
We investigated the ability of the NPV1 plasmid-
expressing nucleoprotein (NP) of influenza virus
strain A/PR8/34 (PR8) to induce cytotoxic immune
responses following i.m. inoculation of newborn
BALB/c mice. Previous studies showed that injection
of NPV plasmid in adult mice primed a strong CTL
response that protected the animals after challenge
with a heterologous strain of influenza virus (Ulmer et
al., 1993). It is known that whereas hemagglutinin
(HA) encodes the major B and Th epitopes respons-
ible for the generation of protective antibodies
(Virelizier, 1975), NP and other inner proteins encode
CTL epitopes that participate to the clearance of virus
(Yap et al., 1978; Lin and Askonas, 1981; Lukacher et
al., 1984). It was shown that anti-NP antibodies do not
mediate any protective effects (Epstein et al., 1993).
Thus, we asked the question if persistent antigen
exposure following DNA immunization of newborn
mice primes a protective cellular immune response or,
alternatively, induces specific immunological toler-
ance.
RESULTS
CTL Priming by Neonatal Immunization with
NPVI Plasmid
To determine the response of BALB/c mice
immunized as newborns with NPV1 plasmid, we
studied the primary and secondary cytotoxicity of
splenocytes from animals sacrificed at ages of 1
(Figures 1A and 1B) and 3 months (Figures 1C and
1D), respectively. Half of the animals were boosted
with PR8 live virus i.p. week previous to sacrifica-
tion, in order to assess the responsiveness of neonates
immunized with NPV plasmid to influenza virus. We
carried out in parallel, analogous experiments in adult
BALB/c mice and we included several controls in
both age groups. As shown in Figure 1A, both
neonates and adult mice immunized with NPV1 and
boosted with live PR8 virus displayed significant
primary cytotoxicity for the NP 147-155 peptide, the
major CTL epitope of NP in the H-2
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contrast, neither the mice injected with control
plasmid (CP) and boosted with PR8 virus 1 week
prior to sacrification (Figure 1A) nor the neonates
immunized at birth with 5 g PR8 virus and boosted
with virus 3 weeks later (data not shown) displayed
primary cytotoxicity against the same peptide. After
in vitro expansion with PR8-infected BALB/c spleno-
cytes, adult and newborn mice immunized with NPV
plasmid or PR8 virus displayed significant secondary
cytotoxicity for NP 147-155 peptide (Figure 1B).
Mice immunized with NPV1 plasmid and boosted
with PR8 virus consistently exhibited the highest
specific lysis values. No primary or secondary CTL
activity was observed in the case of animals injected
only with CP, which lacks the NP open-reading frame
(Figure 1A). These results indicate that NPV1
immunization had a significant priming effect on the
generation of NP-specific CTLs, both in neonate and
adult BALB/c mice. Similar results were obtained in
animals studied 3 months after the completion of
immunization with NPV1 (Figures 1C and 1D),
showing that CTL immunity primed by NPV1
injection of neonates persists at least 3 months.
To estimate more precisely the priming effect of
NPV1 injection in neonates and adult mice, we
carried out CTL precursor (pCTL) frequency estima-
tion by limiting dilution analysis using splenocytes
from animals immunized with plasmid or PR8 virus,
or immunized with NPV1 and boosted with PR8
virus. As shown in Figure 2, mice immunized as
neonates or adults with NPV1 and boosted with PR8
virus displayed higher frequencies of PR8 virus-
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FIGURE Primary (A and C) and secondary (B and D) cytotoxic activity of splenocytes from mice immunized month (A and B) or 3
months (C and D) previously with NPV1 plasmid. Mice were immunized, as described in Materials and Methods, and sacrificed after 4 or
12 weeks since the last inoculation with plasmid or week after i.p. inoculation of PR8 virus, respectively. For the secondary CTL assay,
responder cells were stimulated with PR8 virus. Target cells were NP 147-155 peptide-coated or uncoated P815 cells. The results at E:T
160:1 in the case of primary cytotoxicity (A and C) and E:T 100:1 for the secondary cytotoxicity (B and D) are shown as a mean of percent
specific lysis +SD in groups of three mice. Results at lower E:T ratios are consistent with those shown in the figure.200 A. BOT et al.
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FIGURE 2 Frequency of PR8-virus specific pCTLs in spleens of mice immunized as adults (A) or neonates (B) with NPV1 plasmid. The
immunization with NPV1 was completed 4 weeks before analysis. Some mice were boosted with live PR8 virus 7 days previous to
sacrification. Responder cells pooled from three mice in each group were cultured in 24 replicates at each titer before 5-day stimulation with
irradiated BALB/c splenocytes infected with PR8 virus. Microcyto toxic assays were carried out against PR8-infected or noninfected P815
target cells. 1/pCTL frequency was estimated after linear regression (-1.0 < < -0.95 in all cases). Relative frequency of pCTLs was
estimated against the pCTL frequency in spleens of PR8-immunized BALB/c mice.
specific pCTL in the spleen as compared with animals
immunized with PR8 or NPV1 alone. Immunization
with NPV1 primed two to five times less pCTLs as
compared with the live virus. Notably, the efficacy of
immunization with NPV1 was approximately two
times higher in adult mice versus neonates, as shown
by a comparison of the relative frequency data (Figure
2). Thus, neonatal injection ofNPV was followed by
the priming of virus-specific CTLs rather than
tolerance induction.
IFNy Production by T Cells Primed Subsequent
to Neonatal Immunization with NPV1
As an independent means to assess the priming of
virus-specific T cells following the neonatal injection
of plasmid, we measured the production of IFNy by T
splenocytes. One month after the completion of
immunization with NPV 1, T cells were harvested and
restimulated in vitro with NP 147-155 peptide in
presence of APCs. Estimation of IFNy concentration
in the supernatants showed significantly higher values
in the case of mice immunized with NPV1 and
boosted with PR8 virus, compared to mice immunized
with PR8 virus alone (Figure 3A). No significant
IFNy production was noted in the case of non-
fractionated T cells from mice immunized as new-
borns with NPV1 alone. Enrichment of CD8 T cells
by negative selection previous to in vitro restimula-
tion revealed significant concentrations of IFNy
produced by cells from mice immunized as neonates
with NPV1 alone (Figure 3B). No IL-4 was detected
in culture supernatants following restimulation of T
cells with NP 147-155 peptide, irrespective of the
immunization protocol (data not shown). Together,
these data show that NPV1 inoculation of newborn
mice primed NP 147-155-specific CD8 T cells with
the ability to produce IFNy and to expand subsequent
to the virus restimulation.
Cross-Reactivity of CTLs Primed by Neonatal
Immunization with NPV1
We further investigated the cross-reactive pattern of
CTLs induced by NPV1 immunization of newborn
mice by performing secondary cytotoxic assays after
in vitro expansion with PR8 infected stimulator cells.
As target cells, we used P815 cells infected with A/CTLS INDUCED BY NEONATAL DNA VACCINATION 201
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FIGURE 3 IFNy production of T cells from mice immunized as newborns with NPV1. Nonfractionated T cells from newborn mice
nonimmunized or immunized with NPV and boosted or not with PR8 virus were incubated with APCs in presence of various concentrations
of NP 147-155 peptide (A). In a different experiment (B), nonfractionated or CD4-depleted T cells from mice immunized as newborns with
NPV1 were restimulated in vitro with NP 147-155 peptide. In all cases, T cells were pooled from three mice in each group. IFNy
concentration in supernatants was measured by ELISA and results were expressed as mean of triplicates _+SD. (*) p of the test < 0.05.
PR8/34, A/HK/68, A/Japan/57, or B/Lee/40, respec-
tively. It was previously established that whereas NP
of influenza viruses type A is relatively conserved
even among various subtypes, major differences
occur in HA (reviewed in Krug, 1989). As shown in
Figure 4, splenocytes from mice immunized with
NPV1, PR8 virus or immunized with NPV1 plasmid
and boosted with PR8 virus displayed significant CTL
activities against type A influenza viruses but not
against B/Lee virus, which is a type B influenza virus.
Again, mice immunized with NPV 1 and boosted with
PR8 virus showed the highest secondary cytotoxic
activities, confirming the priming ability of NPV1 in
neonates (Figure 4B). Concordant with previous
studies showing that NPV1 induces type A cross-
reactive CTLs in adult mice (Ulmer et al., 1993),
these results demonstrate the same cross-reactive
ability of CTLs primed by NPV1 injection of
newborns.
Pulmonary Virus Titers in Mice Immunized with
NPV1 as Neonates and Challenged with Lethal
Doses of Influenza Viruses
The protective ability of immunity induced by NPV 1
in neonates and adult mice was investigated following
aerosol infection with one LDloo of PR8 or HK virus
1 and 3 months after completion of immunization.
Pulmonary virus titers were estimated in groups of
three mice at day 3, 7, and 16 after infection. As
shown in Table 1, whereas PR8-immunized adult
mice displayed no virus on day 3 after homologous
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FIGURE 4 Cross-reactivity of CTLs from 3-month-old mice immunized as neonates with NPV1 plasmid. Splenocytes were pooled from
three animals in each group and expanded in vitro with PR8-infected APCs. Target cells were P815 cells noninfected and infected with type
A viruses (open simbols) or B/Lee virus. Results were expressed as percent-specific lysis values for various E:T ratios in the case of PR8-
immunized mice (A), NPV1 immunized and PR8 boosted (B), or NPV1 immunized mice (C).202 A. BOT et al.
TABLE Effect of Immunization with NPV Plasmid on Pulmonary Virus Titer after Lethal Aerosol Challenge with PR8 or HK Influenza
Viruses
Animal groups Immunization Pulmonary virus titer
Day 3 Day 7 Day 16
Challenge with PR8
Adult Nil 4.6 0.5 3.8 +_ 0.1
month after immunization PR8 virus 0 0 ND
Control plasmid 4.8 0.1 3.7 0.5 +
NPV1 plasmid 4.0 0.3 0.9 _+ 1.5 0
Adult NPV plasmid 4.8 +_ 0.1 0.2 +_ 0.2 0
3 months after immunization
Newborn Control plasmid 5.9 _+ 0.0 4.6 0.2 +
month after immunization NPV1 plasmid 4.5 1.2 1.2 2.1 0
Newborn
3 months after immunization NPV1 plasmid 4.1 _+ 0.5 0.9 _+ 1.2 0
Challenge with HK
Adult Nil 6.4 _+ 0.7 5.7 _+ 0.3
month after immunization PR8 virus 5.7 _+ 0.3 0
Control plasmid 6.8 0.1 5.7
NPV1 plasmid 5.8 0.1 0.6 _+ 1.1
Adult NPV1 plasmid 4.3 0.4 0
3 months after immunization
Newborn Control plasmid ND ND
month after immunization NPV1 plasmid 6.6 _+ 0.3 5.1 0.6
Newborn
3 months after immunization NPV1 plasmid 5.6 _+ 0.2 0
ND
apulmonary virus titer was estimated by chicken red blood cell hemagglutination after 48 hr incubation of serial dilutions of tissue
homogenates with MDCK cells. The results are expressed as mean _+SD of loglo TCIDso measured individually for each animal in groups
containing three mice.
bMice were challenged with one LDoo aerosolized PR8 virus (1.5 104 TCIDso) or HK virus (1.5 105 TCIDso) at day 0 and three mice
were sacrificed at day 3 and 7 after infection. All survivor mice were sacrificed at day 16 and pulmonary lung titers were measured.
CMice were immunized i.p. with live PR8 virus 7 days previous to sacrification.
aNo surviving mice at day 16 after challenge.
Measurement of pulmonary virus titer was not carried out.
infection, significant pulmonary virus titers were
noted on day 3 following the challenge with HK virus.
Adult mice immunized with PR8 and challenged with
HK virus cleared the pulmonary virus between day 3
and 7 after infection. In contrast, mice noninjected or
injected with CP failed to clear the virus and did not
survive until day 16 following the challenge. In terms
of virus lung titers, no significant differences were
noted between mice immunized with NPV1 and
nonimmunized mice on day 3 following homologous
or heterologous challenge. In contrast, at day 7
following PR8 virus infection, significant decrease of
pulmonary virus titer was noted in case of adult and
newborn mice immunized with NPV1 at 1 or at 3
months after completion of immunization (in all
cases, p of test < 0.05). All mice immunized with
NPV1 that survived until day 16 after infection
completely cleared the virus from their lungs. Similar
results were noted following heterologous challenge,
except the group of mice immunized as newborns and
challenged month later that failed to clear the virus.
Interestingly, when infected at the age of 3 months,
mice immunized with NPV1 as neonates and chal-
lenged with HK virus cleared the virus by day 7.
Thus, the kinetics of virus reduction in lungs of mice
immunized with NPV1 as adults or neonates is
consistent with a protective role for T-cell immunity,
in particular virus-specific CTLs.CTLS INDUCED BY NEONATAL DNA VACCINATION 203
Survival of Mice Immunized as Neonates with
NPV1 and Challenged with Lethal Doses of
Influenza Viruses
CTLs plays important roles in effective recovery from
viral pneumonia and limitation of DTH lesions.
We also followed the survival of NPVl-immunized
adult and neonates after challenge with one LDloo of
PR8 or HK virus (Figure 5). Adult mice immunized
with NPV1 and challenged 1 or 3 months later with
PR8 virus displayed a statistically significant survival
rate (p of Fisher’s test < 0.05) compared with control
mice nonimmunized or injected with CP (Figures 5A,
5B, and 5C). Although PR8 immunization conferred
100% protectivity, the percentage of survivors was
lower in the case of NPVl-immunized mice, under-
lining the role of virus-specific protective antibodies.
Newborns immunized with NPV1 displayed no
significant survival month later after lethal chal-
lenge with PR8 virus (p > 0.10; Figure 5B). In
contrast, 3-month-old mice immunized as neonates
with NPV1 plasmid showed a statistically significant
survival rate after infection with the same dose ofPR8
virus, comparable to that noted in adult mice
immunized with NPV plasmid (p < 0.05; Figure 5C).
Lower survival rates were noted in mice immunized
as neonates or adults with NPV and challenged with
one LDloo of HK virus (Figures 5E and 5F). Again,
slightly higher protection was evident in mice chal-
lenged 3 months after the completion of immuniza-
tion.
Local Recruitment of Effector Cells in Mice
Immunized as Newborns with NPV1 and
Challenged with PR8 Virus
In order to better characterize the protective mecha-
nisms triggered by NPV1 immunization of newborn
mice, we estimated the number of PR8-specific
pCTLs in the lungs of 3-month-old mice following
aerosol challenge. Compared with nonimmunized
age-matched BALB/c mice, 3-month-old mice
immunized as neonates with NPV 1 plasmid displayed
increased numbers of specific pCTL in lungs and
spleens (Table 2). On a ratio basis, the difference was
more important in lungs at day 3 after infection,
suggesting that an early local recruitment of specific
Persistence of the Plasmid at the Site of Injection
We studied the presence and persistence of NPV1
plasmid in gluteal muscle and anterior tibial muscle of
mice immunized as newborns and adults, respec-
tively. Surprisingly, whereas the plasmid was easily
detectable at the site of injection in adult mice
month after immunization, neonates immunized with
NPV1 displayed weak PCR signals at the age of
month (Figure 6). At 3 months after the completion of
immunization, some adult mice still presented detect-
able plasmid at the site of injection. In contrast,
plasmid was detected in none of the mice immunized
as newborns and studied 3 months later (Figure 6).
These results suggest that the persistence of the
plasmid at the injection site is more limited in mice
injected as neonates. Whereas the plasmid persisted
more than 3 months in some mice immunized as
adults, it persisted less than that in all of the mice
immunized as newborns.
DISCUSSION
Injection of newborn mice with NPV1 led to the
priming of CTLs with the ability to lyse virus-infected
cells and to secrete IFNy following restimulation with
NP 147-155 peptide, which is recognized in context
of MHC-I molecules. The primary cytotoxic assay
results and the estimation of virus-specific pCTL
frequency in spleens of mice immunized with NPV1
and boosted with virus indicated that CTLs primed
during the early period of life have the ability to
proliferate on subsequent antigen exposure. This
conclusion was confirmed by in vitro proliferation of
T cells from mice immunized as newborns with
NPV 1, following restimulation with PR8 virus or NP
147-155 peptide (data not shown). Furthermore,
CTLs primed by neonatal immunization with plasmid
were promptly recruited into the lungs of mice
infected with virus and contributed to the clearance of
virus and the increased survival following lethal204 A. BaT et al.
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FIGURE 5 Survival of NPV1 plasmid-immunized mice challenged with lethal doses of PR8 or HK viruses. Control animals:
Nonimmunized neonates, nonimmunized adults, and CP-injected or PR8-immunized adults are shown in panels A and D. Adult (closed
symbols) or newborn (open symbols) mice were immunized with NPV1 and infected with a dose of 1.5 104 TCIDso PR8 virus (B) or
3 (C) months after the last plasmid inoculation. In parallel experiments, mice were infected with 1.5 105 TCIDso ofHK virus at (E) or
3 (F) months after the completion of immunization. Each group was composed of five to ten animals and the percent of survivors was
represented against time since challenge. Mice that survived until day 20 recovered their original weight and displayed no infectious virus
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TABLE II Frequency of CTL Precursors in Lungs and Spleens of 3-Month-old Mice Challenged with a Lethal dose of Influenza Virus
Group Day post Spleen Lung
challenge 1/Frequency Total 1/Frequency Total
BALB/c immunized with NPV
BALB/c nonimmunized
3 1.3 105 103 6.3 104 2 102
7 2.4 )< 104 4.2 103 5.2 103 2 )< 103
3 6.6 105 102 5.5 105 10
7 6.3 104 9.8 102 9.4 X 103 6.4 102
aResponder cells were pooled from three mice in each group. Lungs were first minced and treated with colagenase. Plastic adherent cells
were removed and twofold dilutions of responder cells were incubated for 5 days with PR8-infected, irradiated BALB/c splenocytes.
Microcytotoxicity was carried out against PR8-infected or noninfected P815 cells and 1/pCTL frequency was estimated by linear regression
(- 1.0 < < -0.97).
bTotal pCTL number/organ was estimated taking into acc.ount the total number of separated cells.
CMice were immunized with 3 30/zg NPV1 at day 1, 3, and 6 after birth.
infectious challenge. Taken together, the data show
that newborn mice immunized with a plasmid encod-
ing NP of PR8 virus develop specific CTL immunity
like the adult mice. This suggests that continuous
exposure of neonate lymphocytes to antigens follow-
ing DNA immunization leads to priming rather than
tolerance induction. Furthermore, the boost effect of
the PR8 virus noted in 4-week-old mice previously
immunized with NPV1 as neonates indicated that
significant CTL priming occurred during the first
month of life. This is unexpected in light of previous
studies that suggested that neonates are more suscept-
ible to high-dose tolerance induction (Billingham et
al., 1956). Thus, the expression of the antigen
following DNA injection does not reach the threshold
required for peripheral tolerance in the case of NPV 1
plasmid. It results that the professional APCs are
mainly, involved in the presentation of antigen to the
neonatal lymphocytes following NPV1 injection. As
recently shown, although neonate lymphocytes were
susceptible to tolerance induction when exposed to
nonenriched populations of splenic APC, dendritic
cells were able to prime a cytotoxic immune response
in newborn mice (Ridge et al., 1996). Further, i.m.
injection ofNPV 1 in newborn mice was not followed
by central tolerance because 1- and 3-month-old mice
responded to PR8 virus. This result, together with the
observation that progenies of mothers immunized
with NPV1 mounted normal CTL responses to the
PR8 virus (manuscript in preparation), suggested that
only very small amounts ofNP protein are eventually
released into the circulation in quantities below the
threshold required for central tolerance induction.
CTLs primed by neonatal immunization with
NPV 1 displayed a similar specificity to those induced
by adult immunization. This conclusion is supported
by the presence of CTLs specific for the immunodo-
minant NP 147-155 epitope previously characterized
in adult mice (Taylor et al., 1987) and by the cross-
reactivity against two virus strains of a distinct
subtype. Thus, the development of CTL repertoire
might follow a distinct pattern compared, for exam-
ple, to the development of the B-cell repertoire.
Previous studies demonstrated a delayed acquisition
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FIGURE 6 Persistence of NPV1 plasmid at the site of injection. PCR analysis ofDNA extracted from tibial anterior muscles (adults, lanes
4 to 7) and gluteal muscles (neonates, lanes 8 to 11), month (A) or 3 months (B) since the last inoculation with plasmid, was carried out
as described in Materials and Methods. As a marker, we used 1-kb DNA ladder (lane 1) as a positive control NPV1 plasmid that gives a
711-bp PCR product (lane 2) and as a negative control, CP plasmid (lane 3). The results were confirmed by a second, independent
experiment.206 A. BOT et al.
of the ability of B cells to respond to cross-reactive
epitopes of influenza virus (Cancro et al., 1979).
Quantitative rather than qualitative differences in
terms of CTL immunity were noted between mice
immunized with NPV1 as neonates or adults, respec-
tively. Estimation of pCTL frequency in spleens of
mice immunized as adults or neonates with NPV1 1
month previously showed a lower expansion of the
virus-specific population in the latter. This seems to
be due simply to the lower number ofT cells in young
organisms, because the plasmid persisted at least 1
month in both age groups. Furthermore, 3-month-old
mice immunized as neonates with NPV 1 displayed an
enhanced protection and increased numbers of virus-
specific pCTLs in the spleen compared to 1-month-
old mice (manuscript in preparation). These results
suggest that the development of T-cell repertoire
together with the persistence of peripheral antigen
exposure leads to a continuous expansion of the
primed, virus-specific CTLs in young mice
immunized as neonates with NPV1. A slower expan-
sion of the virus-specific CTL pool in the immunized
neonates may explain the reduced protection of
1-month-old mice compared to 3-month-old mice and
adult mice challenged with one LDloo of PR8 or HK
virus. In addition, the LDloo infectious doses for
1-month-old mice are probably lower compared to
those of adult mice.
CTL induced by qPV1 immunization of neonates
displayed cross-reactivity against multiple type A
strains of influenza virus and recognized the major
cross-reactive NP 147-155 epitope. This is parti-
cularly important in the case of neonates, because of
a high antigenic polymorphism of influenza virus
strains faced by a limited ability of the immune
system to respond to microbes in the early period of
life. In spite of the cross-reactivity of CTLs induced
by NPV1 immunization, a slightly reduced hetero-
logous protection was demonstrated in mice
immunized with NPV1 as adults or neonates. This
may be due to a reduced magnitude of the cross-
reactive immunity conferred by NP in our experi-
mental system and probably to a faster replication rate
of the HK virus in the lungs. The discrepancy with a
previous study, which showed complete heterologous
protection (Ulmer et al., 1993), may be explained by
differences in the method of infection. It is known that
aerosol challenge leads to an extensive infection of
the upper and lower respiratory tract that can lead to
fatal DTH lesions of the lungs (Sullivan et al., 1976)
even in the case of successful virus clearance. Thus,
our results showed that even if most of the mice
immunized with NPV1 cleared the pulmonary virus
by day 7 following lethal homologous or heterologous
challenge, fewer of them survived and completely
recovered. Effective early recruitment of the virus-
specific CTL at the site of infection leads to rapid
limitation of infection, prompt decrease of pulmonary
virus titer, and reduced DTH lesions. Although a
slower recruitment of specific CTLs may be still
followed by a reduction of virus titer, DTH lesions
tend to be more extensive and may cause the death of
the animal.
PCR analysis of DNA extracted from muscles at
the site of injection showed a reduced persistence of
NPV1 plasmid in mice injected as newborns. This
could be due to either a faster degradation or to the
lytic activity of CTLs toward somatic cells transfected
with NPV 1. The latter hypothesis seems less probable
because the efficiency of CTL priming was higher in
adult mice that displayed longer persistency of the
plasmid. Instead, in the case of newborns injected
with DNA in the gluteal muscle, the limited persist-
ency might be caused by a higher diffusion of the
plasmid into the rapidly proliferating tissues or to the
increased degradation. In contrast, the anterior tibial
muscles of adult mice rich in conjunctive tissue and
largely composed of nondividing myocytes may
facilitate the retention of the plasmid over longer
intervals. It is not clear yet what is the relationship
between the persistency of the immunological mem-
ory, the plasmid at the site of injection, and the
antigenic stimulation. Whereas some studies showed
that the duration of the memory is strictly dependent
on the continuous exposure to antigens (Gray and
Matzinger, 1991; Oehen et al., 1992), other studies
indicated that memory cells represent a distinctive
subset differentiated from naive cells following
antigen priming (Akbar et al., 1988; Camp et al.,
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DNA-based immunization presents some advan-
tages over classical vaccine approaches currently
employed in neonates and infants. Whereas inacti-
vated and subunit vaccines prime mostly a humoral
immune response, neonatal DNA vaccination with
plasmids encoding NP and HA of influenza virus is
followed by synergistic cellular and humoral
immunity (manuscript in preparation). Other
strategies like the use of live-attenuated vectors
(Aggarwal et al., 1990; Tartaglia et al., 1992) or
strong adjuvants (Harding et al., 1991) lead to
generation of CTL immunity, but side effects and
cost-related problems may eventually limit their
large-scale use. In the case of live-attenuated vac-
cines, the strong tendency of neonates to develop a
Th2 type of immune response to some viral epitopes
may explain the limited efficacy of CTL induction
(Barrios et al., 1996). The prolonged stimulation of
the immune system following DNA injection may
circumvent the requirement for boosts carried out in
the case of inactivated vaccines and may lead to a
long-term immunity. Regarding the possible side
effects like oncogenesis, a recent study estimated that
the rate of mutagenesis induced by DNA injection is
significantly lower than the spontaneous chance of
genome mutation (Nichols et al., 1995). In light of
these properties, large-scale DNA vaccination
strategies may be used to ,prevent the horizontal or
vertical transmission of serious infectious diseases iia
infants and children, caused by HIV, HBV, Plasmo-
dium, and so forth, in endemic geographical regions.
Conversely, newborn DNA vaccination may be
employed to a limited extent during periods of
epidemics or in targeted recipients, for prevention of
diseases transmitted by filoviruses, influenza virus,
RSV, rotaviruses, and other infectious agents.
In conclusion, these results show that newborn
DNA vaccination with a plasmid-encoding NP of
influenza virus primed a CTL response, like in adult
organisms. The cellular immunity primed by NPV1
injection of neonates was cross-reactive against
various type A strains of influenza virus and mediated
a protective effect in terms of both survival and virus
clearance. The protectivity conferred by NPV1
immunization was associated with early local recruit-
ment of specific pCTLs following aerosol infection
with influenza virus. It results that continuous expo-
sure of the neonate immune system to antigens
following DNA-based immunization leads to priming,
rather than tolerance induction as predicted from the
higher susceptibility of newborns to high-zone toler-
ance. Based on these findings, DNA immunization
may be used in infants and children to prevent the
transmission of serious infectious diseases.
MATERIALS AND METHODS
Mice
BALB/c mice (H-2a) were purchased from Jackson
Laboratory (Bar Harbor, ME). Mice were housed and
bred at Mount Sinai Animal Care Facility according
to federal and local regulations.
Plasmids, Peptide, and Viruses
NPV1 plasmid was constructed at Merck Research
Laboratories (West Point, PA) by inserting the open
reading frame of the NP gene of A/PR8/34 virus into
the Bgl II site of a mutated pBR322 plasmid,
containing 1.96 kb of enhancer, promoter, and intron
A of the initial early gene of CMV (Ulmer et al.,
1993). The control plasmid (CP) was obtained by
excising the NP open reading frame from NPV1
plasmid. The plasmids were propagated in E. Coli and
purified by the alkaline lysis method. DNA was
ethanol-precipitated and resuspended in 0.9% saline
to a concentration of 30/zg/100/zl for immunization.
The synthetic peptide NP 147-155 with the
sequence TYQRTRALV, which is a major CTL
epitope in the H-2a haplotype (Taylor et al., 1987),
was synthesized in the Protein Core Facility of Mount
Sinai School of Medicine. The NP 147-155 peptide
was used for coating P815 mastocytoma target cells at
a concentration of 0/zg/2.5 104 target cells/ml.
The influenza virus strains A/PR8/34 (H1N1), A/
HK/68 (H3N2), A/Japan/57 (H2N2), and B/Lee/40
were grown in an allantoic cavity of 10-day-old
embrionated hen eggs. Allantoic fluids were harvested
48 hr later and stored at -80C.208 A. BOT et al.
Immunization and Infection
Adult BALB/c mice were immunized with 3 30/g
NPV1 or CP plasmid at 3-week intervals in the
anterior tibial muscle of the right leg. Neonates were
immunized with 3 30/g of plasmid at day 1, 3, and
6 after birth in the right gluteal muscle. Some of mice
were immunized i.p. with live PR8 virus diluted in
200-/A saline at a dose of 1 104 TCIDso.
Mice were challenged with aerosols containing a
lethal dose (LDloo) of 1.5 104 TCIDso PR8 or 1.5
105 TCIDso HK virus. The allantoic fluid was diluted
in saline and the infection was carried out using an
aerosol chamber to which a nebulizer (Ace Glass,
NY) was attached. Immunized and control mice were
infected simultaneously. Mice were observed each
day after infection in terms of survival and weight.
Long-term survivors were considered the mice that
recovered their original weight and did not display
any infectious virus in their lungs at day 20 after
challenge.
Estimation of Pulmonary Virus Titer
Three mice in each group were sacrificed by cervical
dislocation at day 3 and 7 after challenge and the
lungs were harvested and homogenized in PBS-0.1%
gelatin. Triplicates of tenfold dilutions from lung
homogenates were prepared in DMEM-1% BSA and
incubated for 1 hr with MDCK (Madine Darby
Kidney Carcinoma) cells previously washed with
Trypsin-EDTA medium. After adding DMEM-10%
FCS, the plates were incubated for 48 hrs at 37C and
5% CO2. Supernatants were harvested and co-
incubated for 30 min at room temperature with a
suspension of 0.5% chicken red blood cells in 96-well
round-bottom flexible plates (Falcon) as previously
described (Isobe et al., 1994). Virus titers were
estimated by interpolation of the dilution that showed
hemagglutination in 50% of wells (Reed and Muench,
1938).
Cell Preparation and Cytotoxic Assay
Spleens and lungs were aseptically removed from
immunized or infected mice and single-cell suspen-
sions were prepared by mincing and passing the tissue
through cell strainers (Falcon). The lung tissue was
pretreated with 8 U/ml collagenase (Sigma, MO) for
90 min at 37C, as described previously (Stein-
Streilein et al., 1983). The plastic adherent cells were
removed and erythrocytes were lysed by hypotonic
shock. Primary cytotoxic assay was carried out by
incubating various numbers of effector cells immedi-
ately separated from organs, with 5 10351Cr
labeled P815 target cells in presence of NP147-155
peptide or previously infected with PR8 virus (1
104 TCIDso/1 106 target cells for 1 hr at 37C).
After 5-hr incubation in U-bottom plates at 37C in
5% CO2, the supernatants were harvested and radio-
activity released was determined in a y-counter
(Automatic/Wallac-Finland).
For the secondary cytotoxic assays, mixed lympho-
cyte cultures were prepared and incubated for 5 days
in RPMI supplemented with FCS 10%, 50
2-mercaptoethanol, 1% nonessential amino acids, and
2% HEPES buffer, at a density of 2 106 responder
cells/ml. Equal numbers of irradiated, PR8-infected,
haplotype-compatible splenocytes (108 cells in 1.5 ml
DMEM-I% BSA + 2 105 TCIDso virus at 37C for
1 hr) were added to cultures. The secondary cytotoxic
assay was conducted as described previously, after
carefully washing the effector cells obtained from the
cultures. Background activity was estimated using
noncoated, noninfected P815 cells as targets. All
results were expressed as % specific lysis [100
(actual-spontaneous release)/(maximum-spontaneous
release)] background release +_SD of triplicate
determinations.
pCTL Frequency Estimation by Limiting Dilution
Analysis
To evaluate the frequency of pCTL in spleens and
lungs of immunized and infected mice, single-cell
suspensions were prepared and incubated as twofold
dilutions (six dilution steps, beginning with 2.5 105
cells/well) and 24 replicates for each dilution, in
96-well round-bottom plates. Before 5-day incubation
at 37C and 5% CO2, 2.5 105 irradiated, PR8-
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to each well. Individual cultures were tested against
PR8-infected or noninfected 51Cr-labeled P815 target
cells. Positive wells were considered those that
displayed a percentage release greater than back-
ground + 3 SD. The percentage of cultures in every
dilution step regarded as negative for specific cytotox-
icity was plotted logarithmically against the number
of responder cells/well and the 1/pCTL frequency was
estimated after linear regression by the intercept at
37% negative cultures (Lefkovits and Walkmann,
1979). All linear regression coefficients r were
between 1 and -0.95.
PCR products of 711 bp were visualized using
ethidium-bromide-stained agarose gels.
Statistical Analysis
In the case of normal distributions like loglo of
pulmonary virus titers or cytokine concentrations, we
applied Student’s test after running a statistical test
for the sample variances (F test). In the case of
binomial distributions like the survival data, we
computed the p values of statistical significance by
Fisher’s exact test (Rosner, 1995).
Estimation of IFN 3/ Production by T Cells
A number of 2 105 T cells purified on nylon-wool
columns (Nycomed Pharma, Norway) were incubated
with 1 105 irradiated BALB/c splenocytes in the
presence of various concentrations of NP 147-155
peptide in 96-well flat-bottom plates for 4 days.
Recombinant mouse IL-2 (Boehringer Mannheim) at
a concentration of 6 U/ml was added to the cultures.
Supernatants were harvested and IFN,/ or IL-4
concentration was estimated by ELISA (BioSource,
Camarillo, CA). In alternative protocols, CD4 T cells
were previously depleted using magnetic beads cou-
pled with goat anti-rat IgG (PerSeptive Diagnostics,
Cambridge, MA) and rat anti-CD4 mAb (GK 1.5).
Plasmid Detection by PCR
Injected and noninjected muscle tissues were
removed 1 or 3 months after completion of immuniza-
tion with NPV1 plasmid, immediately frozen in
ethanol-dry ice and stored at -80C. Frozen tissue
was thawed and homogenized in lysis buffer (25 mM
Tris, 2 mM CDTA, 2 mM DTT, 10% glycerol, and
1% Triton X), as previously described (Ulmer et al.,
1993). After phenol-chloroform extraction of DNA,
40-cycle PCR reactions were carried out using a PCR
Reagent System Kit (Life Technologies) with the
following NP-specific primers:
forward: 5’-CATTGTCTAGAATTT-
GAACTCCTCTAGTGG
reverse: 5’-GGCCGTCGACCATGAT-
GATCTGGcATTCC
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